Amgen ends Advaxis immuno-oncology deal

Dec. 14, 2018

Amgen has terminated its collaboration with New Jersey-based Advaxis on an immuno-oncology program.

In a filing with the U.S. Securities and Exchange Commission, Advaxis said it received a written notice of termination from Amgen saying the drugmaker was ending the ADXS-NE partnership, a preclinical program that uses Advaxis’ proprietary Listeria monocytogenes attenuated bacterial vector. Advaxis' bacterial vector activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor.

The deal, which was first inked in August 2016, will end in February 2019.

Advaxis said it will be evaluating whether or not to find a new developmental partner for the ADX-NEO program.